Literature DB >> 9807658

Human cytochrome P450 enzymes expressed in bacteria: reagents to probe molecular interactions in toxicology.

E M Gillam1.   

Abstract

1. Phase I metabolism of drugs is accomplished by the concerted actions of a limited number of cytochrome P450 enzymes with wide but often overlapping substrate specificites. Although metabolism generally accelerates the clearance of drugs, reactive products may also be generated that cause toxic effects. 2. Because individuals vary in the range and levels of different P450 forms, it is useful to be able to determine the specific isoforms involved in a particular metabolic reaction, in order to estimate the extent of variation within a population in the pharmacokinetics of specific drugs. Such studies may also allow predictions to be made regarding the relative susceptibility of different individuals to possible adverse effects associated with drug treatment. 3. Human cytochrome P450 enzymes are now routinely expressed as recombinant proteins in many different systems, including mammalian cell culture, yeast, baculovirus and Escherichia coli. The latter system is particularly useful when large amounts of protein are required for biophysical studies, but can also be adapted to routine examination of pathways of drug metabolism and toxicology. 4. The present review provides an analysis of strategies used for enhancing cytochrome P450 expression in bacteria and for examining the activity of the recombinant proteins. The potential applications of recombinant P450 are discussed, with particular emphasis on investigation of the roles of cytochrome P450 forms in the metabolism and the toxicity of drugs.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9807658     DOI: 10.1111/j.1440-1681.1998.tb02338.x

Source DB:  PubMed          Journal:  Clin Exp Pharmacol Physiol        ISSN: 0305-1870            Impact factor:   2.557


  7 in total

1.  Heterologous expression of human cytochromes P450 2D6 and CYP3A4 in Escherichia coli and their functional characterization.

Authors:  Yan Pan; Badrul Amini Abd-Rashid; Zakiah Ismail; Rusli Ismail; Joon Wah Mak; Chin Eng Ong
Journal:  Protein J       Date:  2011-12       Impact factor: 2.371

2.  Preparative synthesis of drug metabolites using human cytochrome P450s 3A4, 2C9 and 1A2 with NADPH-P450 reductase expressed in Escherichia coli.

Authors:  Robert B Vail; Michael J Homann; Imad Hanna; Aleksey Zaks
Journal:  J Ind Microbiol Biotechnol       Date:  2005-03-01       Impact factor: 3.346

3.  Anti-Oxidative Effect of Cassia auriculata on Streptozotocin Induced Diabetic Rats.

Authors:  N Jeyashanthi; V Ashok
Journal:  Indian J Clin Biochem       Date:  2010-09-14

4.  Cloning and expression of cytochrome P450 enzymes catalyzing the conversion of tyrosine to p-hydroxyphenylacetaldoxime in the biosynthesis of cyanogenic glucosides in Triglochin maritima.

Authors:  J S Nielsen; B L Møller
Journal:  Plant Physiol       Date:  2000-04       Impact factor: 8.340

5.  Quantitative drug interactions prediction system (Q-DIPS): a dynamic computer-based method to assist in the choice of clinically relevant in vivo studies.

Authors:  P Bonnabry; J Sievering; T Leemann; P Dayer
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

6.  Magic-angle spinning solid-state NMR spectroscopy of nanodisc-embedded human CYP3A4.

Authors:  Aleksandra Z Kijac; Ying Li; Stephen G Sligar; Chad M Rienstra
Journal:  Biochemistry       Date:  2007-11-07       Impact factor: 3.162

7.  Single mutations change CYP2F3 from a dehydrogenase of 3-methylindole to an oxygenase.

Authors:  Jaya S Kartha; Konstantine W Skordos; Hao Sun; Clifton Hall; LaHoma M Easterwood; Christopher A Reilly; Eric F Johnson; Garold S Yost
Journal:  Biochemistry       Date:  2008-08-22       Impact factor: 3.162

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.